Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Burosumab in Chinese Pediatric XLH Patients
CTR20210505Phase 4Completed
- Sponsor
- Kyowa Kirin
- Start
- Mar 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of burosumab in X-linked hypophosphataemia (XLH), osteomalacia, sponsored by Kyowa Kirin. Started Mar 2021; status: completed.
02
Drugs
burosumab
03
Conditions
X-linked hypophosphataemia (XLH)osteomalacia
Beyond the preview
Go deeper on CTR20210505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210505.